Krystal Biotech (KRYS) Amortizatization of Intangibles (2019 - 2026)
Krystal Biotech (KRYS) posted quarterly Amortizatization of Intangibles of $26000.0 for Q1 2020, down 61.19% year-over-year from $67000.0 in Q2 2019, and little changed on a QoQ basis from $26000.0 in Q4 2019.
Powered by 
Analysis
Krystal Biotech (KRYS) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Krystal Biotech has reported Amortizatization of Intangibles for 2 years, with the latest figure at $26000.0 in Q1 2020.
- Amortizatization of Intangibles for Q1 2020 came in at $26000.0, down 61.19% year-over-year; the trailing twelve-month figure through Mar 2020 was $185000.0 (changed N/A YoY), and the FY2023 annual result was -$1.3 million, down 190.51% from the prior year.
- Amortizatization of Intangibles held at $26000.0 in Q1 2020, from $26000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $68000.0 in Q3 2019 and troughed at $26000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Krystal Biotech | 10.61 Bn | 9.76 Bn | 112.79 Mn | 210,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 210,000.00 |
| Mar 31, 2026 | 204,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 191,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 233,000.00 |
| Sep 30, 2023 | 230,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 218,000.00 |
| Mar 31, 2020 | 26,000.00 |
| Dec 31, 2019 | 26,000.00 |
| Sep 30, 2019 | 68,000.00 |
| Jun 30, 2019 | 65,000.00 |
| Mar 31, 2019 | 67,000.00 |